Advice
Following a full submission
histrelin (Vantas) subcutaneous implant is accepted for restricted use within NHS Scotland for palliative treatment of advanced prostate cancer. Histrelin is restricted to use in patients with an anticipated life expectancy of at least one year in whom annual administration will offer advantages.
In a single-arm study, histrelin provided effective suppression of testosterone levels in patients with advanced prostate cancer. It requires less frequent administration than other leutenising hormone releasing hormone (LHRH) agonists. Other LHRH agonists are available at a lower acquisition cost
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- histrelin acetate (Vantas)
- SMC ID:
- 557/09
- Indication:
- Advanced prostate cancer
- Pharmaceutical company
- Orion Pharma (UK) Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 August 2009